| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Cancer Research Campaign Human Cancer Genetics Research Group, Department of Oncology [P. D. P. P., S. G., B. A. J. P.], and Cancer Research Campaign Genetic Epidemiology Unit, Department of Community Medicine [P. D. P. P., D. F. E.], University of Cambridge Strangeways Research Laboratories, Wort’s Causeway, Cambridge, CB1 8RN; and East Anglian Cancer Intelligence Unit, Department of Community Medicine, Institute of Public Health, Cambridge [D. L. S.], CB1 2SR, United Kingdom
The natural history of hereditary and BRCA1- and BRCA2-associated epithelial ovarian cancer may differ from that of sporadic disease. The purpose of this study was to compare the clinical characteristics of BRCA1- and BRCA2-associated hereditary ovarian cancer, hereditary ovarian cancer with no identified BRCA1/2 mutation, and ovarian cancer in population-based controls. BRCA1 and BRCA2 mutation testing was carried out on index cases from 119 families with site-specific epithelial ovarian cancer or breast-ovarian cancer. We estimated overall survival in 151 patients from 57 BRCA1 and BRCA2 mutation families and compared it with that in 119 patients from 62 families in which a BRCA1/2 mutation was not identified. We compared clinical outcome and data on tumor histopathology, grade, and stage. We also compared survival in familial epithelial ovarian cancer, whether or not a mutation was identified, with that of an age-matched set of population control cases. Overall survival at 5 years was 21% (95% confidence interval, 14–28) in cases from BRCA1 mutation families, 25% (8–42) in BRCA2 mutation families, and 19% (12–26) in families with no identified mutation (P = 0.91). Survival in familial ovarian cancer cases as a whole was significantly worse than for population controls (P = 0.005). In the familial cases, we found no differences in histopathological type, grade, or stage according to mutation status. Compared to population control cases, mucinous tumors occurred less frequently in the familial cases (2 versus 12%, P < 0.001), and a greater proportion of the familial cases presented with advanced disease (83% stage III/IV versus 56%; P = 0.001). We have shown that survival in familial ovarian cancer cases is worse than that in sporadic cases, whether or not a BRCA1/2 mutation was identified, perhaps reflecting a difference in biology analogous to that observed in breast cancer.
This article has been cited by other articles:
|
|
 |
|
  D. S.P. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S. B. Kaye, and M. E. Gore "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations J. Clin. Oncol., December 1, 2008; 26(34): 5530 - 5536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Soegaard, S. K. Kjaer, M. Cox, E. Wozniak, E. Hogdall, C. Hogdall, J. Blaakaer, I. J. Jacobs, S. A. Gayther, and S. J. Ramus BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark Clin. Cancer Res., June 15, 2008; 14(12): 3761 - 3767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer J. Clin. Oncol., January 1, 2008; 26(1): 20 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Sowter and A. Ashworth BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis, October 1, 2005; 26(10): 1651 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. M. Klijn, et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers Clin. Cancer Res., April 1, 2004; 10(7): 2473 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Ramus, P. D. P. Pharoah, P. Harrington, C. Pye, B. Werness, L. Bobrow, A. Ayhan, D. Wells, A. Fishman, M. Gore, et al. BRCA1/2 Mutation Status Influences Somatic Genetic Progression in Inherited and Sporadic Epithelial Ovarian Cancer Cases Cancer Res., January 15, 2003; 63(2): 417 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, M. Hatae, I. Kobayashi, T. Fujii, I. Nagata, K. Ushijima, et al. Mutational Analysis of BRCA1 and BRCA2 and Clinicopathologic Analysis of Ovarian Cancer in 82 Ovarian Cancer Families: Two Common Founder Mutations of BRCA1 in Japanese Population Clin. Cancer Res., October 1, 2001; 7(10): 3144 - 3150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, M. Hatae, I. Kobayashi, T. Fujii, I. Nagata, K. Ushijima, et al. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25 Hum. Mol. Genet., June 1, 2001; 10(13): 1421 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Buller, T. A. Lallas, M. S. Shahin, A. K. Sood, M. Hatterman-Zogg, B. Anderson, J. I. Sorosky, and P. A. Kirby The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer Clin. Cancer Res., April 1, 2001; 7(4): 831 - 838. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. McGuire, A. S. Whittemore, R. Norris, and I. Oakley-Girvan Survival in Epithelial Ovarian Cancer Patients with Prior Breast Cancer Am. J. Epidemiol., September 15, 2000; 152(6): 528 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-H. Wang, W.-Y. Shyong, Y. F. Li, H.-H. Lee, W.-Y. Tsai, H.-T. Chao, C.-Y. Wu, Y.-C. Tsai, and C.-C. Yuan BRCA1 Mutations in Taiwanese with Epithelial Ovarian Carcinoma and Sporadic Primary Serous Peritoneal Carcinoma Jpn. J. Clin. Oncol., August 1, 2000; 30(8): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boyd, Y. Sonoda, M. G. Federici, F. Bogomolniy, E. Rhei, D. L. Maresco, P. E. Saigo, L. A. Almadrones, R. R. Barakat, C. L. Brown, et al. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer JAMA, May 3, 2000; 283(17): 2260 - 2265. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
